
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is poised for success with its innovative approach to targeted oncology therapies and strong clinical data from its ongoing trials. Their multiple clinical-stage product candidates, including darovasertib and IDE849, have shown impressive efficacy in their respective clinical trials, with consistent PFS improvements across all patient subgroups and a manageable safety profile. With upcoming milestones such as the full dataset from the Phase 2/3 OptimUM-02 trial and a potential full approval for one of their candidates, IDYA is well-positioned for continued growth and its current valuation does not fully reflect its potential in the precision medicine market.
Bears say
IDEAYA Biosciences is trading at a premium due to its promising clinical-stage product candidates, but its risks include potential setbacks in R&D and regulatory approval, as well as competition from emerging companies. Additionally, lower than expected product sales and the need for dilutive financing could also be potential concerns for the company's financial outlook. These factors contribute to the analyst's negative outlook on the stock.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares